Chair:
Katy Rezvani, MD, PhD, The University of Texas MD Anderson Cancer Center, USA
Speakers:
Katy Rezvani, MD, PhD, The University of Texas MD Anderson Cancer Center, USA – NK cells: next generation cell therapies for cancer
Blake Aftab, PhD, Adicet Bio, Inc., USA – Development of First-in-Class CAR T Cell Therapies: Data Supporting Clinical and Preclinical Pipeline
Spyridoula (Roula) Vasileiou, PhD, Baylor College of Medicine, USA – Off-the-shelf Virus-Specific T cells to Treat Viral Infections
The allo vs auto debate has gained steam over the past year as highlighted by the first-ever approval of an allogeneic T cell product (Tabelecleucel in Europe). This plenary session will focus on various types of allogeneic therapies – from early stage to late stage – and why allogeneic approaches are in huge demand.
Session Objectives
- Identify the different types of allogeneic cell and gene therapies
- Understand the differences between allogeneic and autologous therapies
- Understand the different approaches to evading host rejection of allogeneic therapies
Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Chair and Speaker
